Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF schedule

Acta Oncologica

Volumn 36, Issue 7, 1997, Pages 701-704

  Ribas, Antoni ^a,b   Albanell, Joan ^a   Bellmunt, Joaquim ^a   Bermejo, Begoña ^a   Gallardo, Enrique ^a   Vera, Ruth ^a   Bodi, Ramon ^a   Solé Calvo, Luís Alfonso ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GROWTH FACTOR; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031407771     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869709001340     Document Type: Article

References (14)

1. Early Breast Cancer Trialist's Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 399: 71-85.
2. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. New Engl J Med 1995; 332: 901-6.
3. Buzzoni R, Bonadonna G, Valagussa P, Zambetti M. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 1991; 9: 2134-40.
4. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995; 273: 542-7.
5. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. New Engl J Med 1994; 330: 1253-9.
6. Habibollahi F, Fentiman IS, Chaudary MA, et al. Influence of radiotherapy on the dose of adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 1989; 13: 237-41.
7. Ribas A, Albanell J, Bellmunt J, et al. Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a sale and cost-effective schedule to maintain dose-intensity. J Clin Oncol 1996; 14: 1573-80.
8. Hryniuk WM, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4: 1162-70.
9. The American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12: 2471-508.
10. Griem KL, Henderson IC, Gelman R, et al. The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J Clin Oncol 1987; 5: 1546-55.
11. Overguard M, Christensen JJ, Johansen H, et al. Evaluation of radiotherapy in high-risk breast cancer patients: Report from the Danish Breast Cancer Cooperative Group (DBCG 82) Trial. Int J Radiat Oncol Biol Phys 1990; 19: 1121-4.
12. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-43.
13. Schmidberger H, Hess CF, Hoffmann W, et al. Granulocyte colony-stimulating factor treatment of leucopenia during fractionated radiotherapy. Eur J Cancer 1993; 29A: 1927-31.
14. Vokes EE, Haraf DJ, Mick R, McEvilly JM, Weichselbaum RR. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol 1994; 12: 2351-9.